Brenda Reynolds, ©iQur

BIA: Three new faces on the board

The BIA has added three new members to the Board of Directors. Calchan CEO Brenda Reynolds (pictured), Immunocore Chief Business Officer Eva-Lotta Allan and Polar Capital’s Partner – Healthcare Dan Mahony will join the board of the British BioIndustry Association from January 2017.
Read more
Researcher at Martinsried-headquarters of Medigene, © Medigene

Medigene offers neoantigen-specific TCRs

Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the company presented a process that delivers neospecific anti-tumour TCRs.

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more